Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-08-22

Clinical Trial Update: A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating casopitant to prevent nausea and vomiting caused by cisplatin-based chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • casopitant (casopitant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Nausea and Vomiting, Chemotherapy-Induced | Phase 3 | Status: COMPLETED